Gastroenterology
Volume 136, Issue 2 , Pages 441-450.e1 , February 2009

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

  • Miguel Regueiro

      Affiliations

    • Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    • Corresponding Author InformationAddress requests for reprints to: Miguel Regueiro, MD, Associate Professor of Medicine, University of Pittsburgh School of Medicine, Co-Director, Inflammatory Bowel Disease Center, Director, Gastroenterology, Hepatology, and Nutrition Fellowship Training Program, Division of Gastroenterology, Hepatology & Nutrition, University of Pittsburgh Medical Center, 200 Lothrop Street, PUH-C Wing Mezzanine Level, Pittsburgh, Pennsylvania 15213. fax: (412) 383-8913
    • ,
  • Wolfgang Schraut

      Affiliations

    • Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    • ,
  • Leonard Baidoo

      Affiliations

    • Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    • ,
  • Kevin E. Kip

      Affiliations

    • Research Center, University of South Florida, College of Nursing, Tampa, Florida
    • ,
  • Antonia R. Sepulveda

      Affiliations

    • Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Marilyn Pesci

      Affiliations

    • Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    • ,
  • Janet Harrison

      Affiliations

    • Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    • ,
  • Scott E. Plevy

      Affiliations

    • Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina

Received 3 September 2008 ,Accepted 23 October 2008.

References 

  1. Cones J, Nion-Larmurier I, Beaugerie L, et al. Impact of increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237–241
  2. Bennell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg. 2000;231:38–45
  3. D'Haens G, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262–267
  4. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualized ileal ulcers preceding symptoms. Gut. 1992;33:331–335
  5. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956–983
  6. Sachar DB. The problem of postoperative recurrence of Crohn's disease. Med Clin North Am. 1990;74:183–188
  7. Michelassi F, Balestracci T, Chappel R, et al. Primary and recurrent Crohn's disease: experience with 1379 patients. Ann Surg. 1991;214:230–240
  8. Terdiman JP. Prevention of postoperative recurrence in Crohn's disease. Clin Gastroenterol Hepatol. 2008;6:616–620
  9. Rutgeerts P, Hield M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995;108:1617–1621
  10. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128:856–861
  11. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127:723–729
  12. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for the prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology. 2005;127:730–740
  13. Domenech E, Manosa M, Bernal I, et al. Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study. Inflamm Bowel Dis. 2008;14:508–513
  14. Sorrentino D, Terrosu G, Avellini C, et al. Prevention of postoperative recurrence of Crohn's disease by infliximab. Eur J Gastroenterol Hepatol. 2006;18:457–459
  15. Sorrentino D, Terrosu G, Avellini C, et al. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med. 2007;167:1804–1807
  16. Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology. 1996;110:424–431
  17. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology. 1996;110:424–431
  18. Mekhjian HS, Switz DM, Watts HD, et al. National Cooperative Crohn's Disease Study: factors determining recurrence of Crohn's disease after surgery. Gastroenterology. 1979;77:907–913
  19. Caprilli R, Corrao G, Taddei G, et al. Prognostic factors for postoperative recurrence of Crohn's disease (Gruppo Italiano per lo Studio del Colon e del Retto (GISC)). Dis Colon Rectum. 1996;39:335–341
  20. Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut. 1988;29:588–592
  21. Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn's disease. Gastroenterology. 1998;115:259–267
  22. Avidan B, Sakhnini E, Lahat A, et al. Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion. 2005;72:563–571
  23. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–869
  24. Wenckert A, Kristensen M, Eklund AE, et al. the long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease (A controlled double blind trial). Scand J Gastroenterol. 1978;13:161–167
  25. Ewe K, Herfarth C, Malchow H, et al. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulphasalazine prophylaxis: a multicenter trial. Digestion. 1989;42:224–232
  26. McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology. 1995;109:404–413
  27. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology. 1995;108:345–349
  28. Lochs H, Mayer M, Fleig W, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology. 2000;118:264–273
  29. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease (The Canadian Mesalamine for Remission of Crohn's Disease Study Group). Gastroenterology. 1997;112:1069–1077
  30. D'Haens G, Norman M, Van Assche G, et al. Severe post-operative recurrence of Crohn's disease is significantly reduced with combination therapy metronidazole and azathioprine: a double-blind controlled randomized trial. Gastroenterology. 2007;132:A289
  31. Pascua M, Su C, Lewis JD, et al. Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease. Aliment Pharmacol Ther. 2008;28:545–556

 The authors disclose no conflicts.

 This work was funded in part by an unrestricted grant from Centocor, Inc Miguel Regueiro, Scott Plevy, and Leonard Baidoo participate or participated as a consultant or speaker for Centocor, Inc.

 Registered with www.clinicaltrials.gov (NCT00688636).

PII: S0016-5085(08)01889-1

doi: 10.1053/j.gastro.2008.10.051

Gastroenterology
Volume 136, Issue 2 , Pages 441-450.e1 , February 2009

Article Tools

* Image Usage & Resolution